CRISPR Therapeutics AG (CRSP) Equity Income (2016 - 2019)

CRISPR Therapeutics AG has disclosed Equity Income across 4 years of filings, most recently posting -$3.4 million for Q3 2019.

• Equity Income for Q3 2019 came in at -$3.4 million, down 238.93% year-over-year; the trailing twelve-month figure through Dec 2019 was -$5.5 million (down 27.88% YoY), and the FY2019 annual result was -$5.5 million, down 27.88% from the prior year.
• Equity Income came in at -$3.4 million for Q3 2019 at CRISPR Therapeutics AG, down from -$1.0 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of -$359000.0 in Q3 2017 to a low of -$35.8 million in Q4 2016.
• The 4-year median for Equity Income is -$1.0 million (2018), against an average of -$3.7 million.
• Across the five-year window, Equity Income surged 98.74% in 2017 and slumped 238.93% in 2019, its largest moves.
• CRISPR Therapeutics AG's Equity Income stood at -$35.8 million in 2016, then soared by 98.74% to -$453000.0 in 2017, then plunged by 124.94% to -$1.0 million in 2018, then tumbled by 236.6% to -$3.4 million in 2019.
• The last three Equity Income figures came in at -$3.4 million (Q3 2019), -$1.0 million (Q2 2019), and -$1.0 million (Q1 2019), per Business Quant data.